EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Dipeptidyl Peptidase 4, a Novel Adipokine, Impairs Retinal Microcirculation in Patients With Type 2 Diabetes Mellitus

Tsuneaki Omae, Shinji Ono, Takayuki Kamiya, Shinichi Otani, Harumasa Yokota, Taiji Nagaoka

Investigative Ophthalmology & Visual Science · 2025

DOI: 10.1167/iovs.66.14.4 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Tsuneaki Omae and 5 co-authors. Institution: Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Diabetic Retinopathy, Microcirculation, Dipeptidyl Peptidase 4. Cited 1 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

The study objective was to examine the role of dipeptidyl peptidase 4 (DPP4) on retinal microcirculation in patients with type 2 diabetes mellitus (DM) and an in vitro study.

Methods

Sixty-seven patients with type 2 diabetes and minimal diabetic retinopathy (DR) were divided into two groups based on gender. We compared the patients' retinal circulatory parameters measured with laser Doppler velocimetry and serum DPP4 concentrations. Using isolated retinal arterioles, we also compared the retinal endothelial function before and after DPP4 incubation.

Results

The plasma DPP4 concentrations were correlated negatively with the retinal vessel diameter (D) and retinal blood flow (RBF) in men but not women. Multiple regression analysis showed that the plasma DPP4 level was independently and negatively correlated with the vessel D. In vitro, intraluminal DPP4 treatment significantly attenuated endothelium-dependent nitric oxide (NO)-mediated vasodilation with a dose-dependent manner. Superoxide scavenger 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), the NADPH oxidase inhibitor apocynin, and the DPP4 inhibitor teneligliptin, prevented the retinal endothelial dysfunction induced by DPP4.

Conclusions

Our results indicated that high serum DPP4 concentration may be associated with decreased RBF, probably via the constricted vessel D in men with type 2 diabetes with early-phase DR and further that DPP4 may inhibit endothelium-dependent NO-mediated dilation in the retinal arterioles via producing superoxide from NADPH oxidase.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Diabetic RetinopathyMicrocirculationDipeptidyl Peptidase 4Retinal VesselsHumansMaleFemaleMiddle AgedLaser-Doppler FlowmetryVasodilationEndothelium, VascularAgedRegional Blood FlowArteriolesNitric OxideRetinal Artery

Substances

Dipeptidyl Peptidase 4DPP4 protein, humanNitric Oxide

Authors and institutions

  • Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan.

Cite

APA

Omae, T., Ono, S., Kamiya, T., Otani, S., Yokota, H., & Nagaoka, T. (2025). Dipeptidyl Peptidase 4, a Novel Adipokine, Impairs Retinal Microcirculation in Patients With Type 2 Diabetes Mellitus. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.14.4

Vancouver

Omae T, Ono S, Kamiya T, Otani S, Yokota H, Nagaoka T. Dipeptidyl Peptidase 4, a Novel Adipokine, Impairs Retinal Microcirculation in Patients With Type 2 Diabetes Mellitus. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.14.4

BibTeX
@article{Omae2025,
  author = {Omae, Tsuneaki and Ono, Shinji and Kamiya, Takayuki and Otani, Shinichi and Yokota, Harumasa and Nagaoka, Taiji},
  title = {Dipeptidyl Peptidase 4, a Novel Adipokine, Impairs Retinal Microcirculation in Patients With Type 2 Diabetes Mellitus},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2025},
  doi = {10.1167/iovs.66.14.4}
}
Start for free →